期刊文献+

阿托伐他汀对高血压大鼠血管纤维化及结缔组织生长因子的影响 被引量:10

Effects of Atorvastatin on Vascular Fibrosis and Connective Tissue Growth Factor in Renovascular Hypertensive rats
下载PDF
导出
摘要 目的:探究阿托伐他汀(atorvastatin)对肾血管性高血压血管纤维化及结缔组织生长因子(CTGF)表达的影响。方法:24只SD大鼠随机分为假手术组(N组)、高血压组(RH组)、阿托伐他汀组(他汀组)各8只;将RH组及他汀组大鼠建立二肾一夹肾血管性高血压(2K1C-RH)大鼠模型。术后4周末,他汀组开始以阿托伐他汀(10mg.Kg-1.d-1)灌胃,共8周。治疗前后RT-PCR法检测各组大鼠收缩压、胸主动脉CTGF、纤维连接蛋白(FN)、Ⅲ型胶原(ColⅢ)的表达,并用免疫组化显示CTGF的表达。结果:与N组比较,RH组大鼠胸主动脉CTG-FmRNA、FNmRNA、ColⅢmRNA显著增加(P<0.01);他汀组与RH组比较则3项指标明显下调(P<0.05)。结论:阿托伐他汀能抑制高血压血管纤维化,可能与下调CTGF的表达有关。 Objective:To investigate the effects of atorvastatin on vascular fibrosis and connective tissue growth factor (CTGF) in renovascular hypertensive (RH) rats. Methods:The following groups of rats were studied: sham group, RH group and atorvastatin (10 mgokg-1od-1)-treated RH group. Systolic blood pressure (SBP) was measured. The mRNA expression of CTGF, FN and ColⅢ was detected by RT-PCR at the 12th week after operation. The expression of CTGF protein was detected by immunohistochemistry. Results: Compared with the normal control group, the mRNA expression of CTGF (P〈0.01), FN and ColⅢ (P〈0.05) in RH group was increased in the thoracic aorta, and atorvastatin could significantly inhibit vascular fibrosis and the expression of CTGF (P〈0.05). Conclusion: Atorvastatin could inhibit the development of vascular fibrosis in RH rats, which was probably related to the decreased expression of CTGF.
出处 《中国康复》 2010年第1期6-8,共3页 Chinese Journal of Rehabilitation
基金 黄科技发农(2007)1号子课题
关键词 他汀类药物 肾血管性高血压 血管纤维化 结缔组织生长因子 statins renovascular hypertension vascular fibrosis connective tissue growth factor
  • 相关文献

参考文献6

  • 1De-las- Heras N, Ruiz-Ortega M, Ruperez M, et al. Role of connective tissue growth factor in vascular and renal damage associated with hypertension in rats. Interactions with angiotensin Ⅱ[J]. Journal of the Renin Angiotensin Aldosterone System,2006,7(4) :192-200.
  • 2边树怀,高晶,黄希正.胶原代谢异常和高血压[J].河北医科大学学报,2006,27(1):66-68. 被引量:2
  • 3Chen M,Lam A,Abraham JA, et al. CTGF expression is induced by TGF-betal in cardiac fibrlblastsand cardimyocytes: a potentisl role in heart fibrosis[J]. J Mol Cell Cadiol,2000,32(10) : 1805-1819.
  • 4Twigg SM, Joly AH, Chen MM, et al. Connective tissue tissue growth factor/IGF-bin-ding protein-related protein- 2 is a mediator in the induction of fibronection by advanced glycosylationen, products in human dermal fibroblasts[J]. Endocrinology,2002,143(4) : 1260-1266.
  • 5Ruperez M, Rodrigues-Diez R, Blanco-Colio LM, et al. HMG-CoA reductase inhibitors decrease angiotensin Ⅱ-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways[J]. Hypertension,2007,50(2) :377-383.
  • 6Luo JD,Zhang WW, Zhang GP,et al. Simvastatin inhibits cardic hypertropy and angiotension-converting enzyme activity in rats with aoutic stenosis[J]. Clin Exp Pharmacol Physiol, 1999,26 : 903 - 908.

二级参考文献16

  • 1黄顺伟,高修仁,唐可京.原发性高血压患者循环中IGF-1水平与心肌肥厚的研究[J].中国病理生理杂志,2005,21(4):696-699. 被引量:10
  • 2Diez J. Querejeta R, Varo N, et al. Serum carboxy- terminal propeptide of pro-collagen type 1 is a marker of myocardial fibrosis in hypertensive heart disease [J], Circulation, 2000,101(14) : 1729-1735.
  • 3Lindsay MM, Maxwell P, Dunn FG. TIMP-1 : a marker of left ventricular diastolic dysfunction and fibrosis in hypertension [J]. Hypertension, 2002,40(2),136 -141.
  • 4Lijncn P.I, Petrov VV, Fagard RH. Induction of cardiac fibrosis by angiotensin Ⅱ[J] . Methods Find Exp Clin Pharmacol, 2000,22(10) : 709 -723.
  • 5Ichihara S,Senbonmatsu T,Price E,et al. Angiotensin 11 type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin Ⅱ-induced hypertension[J]. Circulation, 2001,104 (3) : 346-351.
  • 6Hocher B, Georgc I, Rebstock J, et al. Endothlin system-dependent, cardiae remodeling in reovascular hypertension[J]. Hypertension, 1999,33(3) :816-822.
  • 7Kuwahara F, Kai H, Tokuda K, et al. Transforming growth factor beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressurre- owerloaded rats [J].Circulation, 2002,106(1) : 130- 135.
  • 8Spinalc FG, Coker ML, Bond BR, et al. Myocardial matrix degradation and metalloproteinases activation in the failing heart: a potential therapeutic target [J]. Cardiovasc Res,2000,46(2) : 225-238.
  • 9Duka I, Kintsueashviki E, Gavras I, et al. Vasoactive potential of the B( 1 ) bradykinin receptor in normotension and hypertension [J]. Circ Res, 2001,88(3):275-281.
  • 10Laviades C, Varo N, Fernondez J, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension [J]. Circulation, 1998,98 (6) :535- 540.

共引文献1

同被引文献126

引证文献10

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部